Journal article
Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis
T Uher, EK Havrdova, P Benkert, N Bergsland, J Krasensky, B Srpova, M Dwyer, M Tyblova, S Meier, M Vaneckova, D Horakova, R Zivadinov, D Leppert, T Kalincik, J Kuhle
Multiple Sclerosis Journal | SAGE PUBLICATIONS LTD | Published : 2021
Abstract
Background: The added value of neurofilament light chain levels in serum (sNfL) to the concept of no evidence of disease activity-3 (NEDA-3) has not yet been investigated in detail. Objective: To assess whether combination of sNfL with NEDA-3 status improves identification of patients at higher risk of disease activity during the following year. Methods: We analyzed 369 blood samples from 155 early relapsing-remitting MS patients on interferon beta-1a. We compared disease activity, including the rate of brain volume loss in subgroups defined by NEDA-3 status and high or low sNfL (> 90th or < 90th percentile). Results: In patients with disease activity (EDA-3), those with higher sNFL had high..
View full abstractGrants
Awarded by Biogen
Funding Acknowledgements
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Czech Ministry of Education (project Progres Q27/LF1), the Czech Ministry of Health (project RVO-VFN64165) and the AZV grant NV 18-04-00168. SET study was supported by Biogen. Statistical analysis was supported by Sanofi (GZ-2017-11718).